Looking back at the past year and gearing up for 2021
It has been an interesting year, hasn’t it? Despite the uncertainties 2020 has challenged us with, it has shown the incredible value of medical research, especially in the field of immunology. From new software releases to new scientific publications, it has been a productive year for ENPICOM. We are incredibly proud of what our team, partners, and customers accomplished.
Here is a look-back at our top highlights.
Enhancing the IGX Platform
We remained dedicated to delivering powerful solutions to speed up and simplify the management and analysis of repertoire sequencing data, accelerating the discovery and development of new biological targets. Some of the most prominent new functionalities we developed in the past year are:
- single-cell sequencing data support to help gain a more nuanced understanding of the immune repertoire;
- a new IGX-Compare app to compute and visualize clonal overlap between different sets of receptor sequences;
- more extensive data support including Adaptive, 10x, and MiXCR output;
- interactive V/J gene usage visualizations;
- VDJdb and IEDB database integrations;
- not to mention, improved UI and better performance.
You can visit our release notes for a complete overview of new features.
To democratize the Rep-Seq data management and analysis space, we have launched a free access program. The IGXperience Program provides access to ENPICOM’s professional Rep-Seq data handling and analysis solution at no cost.
Serving life scientists worldwide and unlocking new applications
We were honored to start serving more researchers enabling them to make the most out their experiment data and uncover new insights. For instance, Neogene Therapeutics is now using the IGX Platform to manage, organize, and analyze T cell sequencing data as part of their research and development of personalized neoantigen TCR therapies for cancer. The Princess Margaret Cancer Centre, one of the top five cancer research centers in the world, chose our software solution to streamline the analysis and management of the immune repertoire sequencing data generated in their research and clinical studies.
Facilitating knowledge sharing
2020 has been truly a year of digital collaboration and knowledge sharing. We released several free webinars to take a deep dive into Rep-Seq-related topics. These are still available for you to watch on demand anytime, anywhere.
- Better exploit paired-chain immune repertoire data: Leverage single-cell Rep-Seq data to uncover new biological insights.
- Maximize Rep-Seq data output with end-to-end platform: Manage, analyze, and visualize repertoire sequencing data without bioinformatics skills.
- Accelerate scientific discovery with database integrations: Use public datasets to gain deeper insights.
- Streamline candidate selection with clustering and phylogenetic analysis : Integrate sequencing and assay data to select the best therapeutic candidate.
- Advance your research with Rep-Seq data and the IGX Platform: Applying data to accelerate drug discovery.
Supporting scientific community
Our team had the honor to work together with some of the brightest minds in the biomedical field and contributed to the publication of their findings in the following scientific papers:
- Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system
- Reverse TCR repertoire evolution toward dominant low-affinity clones during chronic CMV infection
- Next‐generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis
- The CMV-Specific CD8+ T Cell Response Is Dominated by Supra-Public Clonotypes with High Generation Probabilities
Innovating and growing non-stop
2020 taught us to stay agile, be creative, and above all remain connected. More colleagues have joined the ENPICOM team and support biotech development projects with passion. In November, we were recognized as on the of the 10 fastest growing data science companies in the Netherlands. Our expanded team will be relocating to a larger office soon.
While lab work was affected, our customers had more time to analyze their data and talk to us. With this deep understanding of their research needs and challenges and with our newly set-up scientific advisory board supporting our team, we will bring a new antibody discovery solution to the market early next year.
Thanks to all our customers, friends and partners for a fruitful, eventful, and fun 2020. We wish you all a most wonderful holiday season and a prosperous and healthy New Year!